The preserved effects of SGLT2 inhibitors on natriuresis and blood pressure may be a pivotal pathway to CV complications, especially heart failure (List and Whaley 2011; Sattar and McGuire 2018). This evidence concerns the gene SLC5A2 and heart failure.